Best Practices for Managing EGFR Tyrosine Kinase Inhibitor–Related Adverse Events

Sponsored by Takeda Oncology

REFERENCES

1. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167-179. doi:10.1016/j.semcancer.2019.09.015

2. Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1(3):e000060. doi:10.1136/esmoopen-2016-000060

3. Harandi A, Zaidi AS, Stocker AM, Lader DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009;2009:567486. doi:10.1155/2009/567486

4.Tarceva. Prescribing information. Astellas Pharma US/Genentech; 2016. Accessed October 24, 2022. https://www.gene.com/download/pdf/tarceva_prescribing.pdf

5. Iressa. Prescribing information. AstraZeneca; 2021. Accessed October 24, 2022. https://medicalinformation.astrazeneca-us.com/home/prescribing-information/iressa-pi.html

6. Gilotrif. Prescribing information. Boehringer Ingelheim; 2022. Accessed October 24, 2022. https://content.boehringer-ingelheim.com/DAM/07c11f94-358a-439d-b0c8-af1e011f04c4/gilotrif-us-pi.pdf

7. Tagrisso. Prescribing information. AstraZeneca; 2022. Accessed October 24, 2022. https://medicalinformation.astrazeneca-us.com/home/prescribing-information/tagrisso-pi.html

8. Vizimpro. Prescribing information. Pfizer; 2020. Accessed October 24, 2022. https://labeling.pfizer.com/ShowLabeling.aspx?id=11019

9. Exkivity. Prescribing information. Takeda Pharmaceuticals; 2021. Accessed October 24, 2022. https://content.takeda.com/?contenttype=pi&product=exkivity&language=eng&country=usa&documentnumber=1

10. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute. Published online November 27, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf

11. Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs. 2008;12(2):283-290. doi:10.1188/08.CJON.283-290

12. Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12(5):610-621. doi:10.1634/theoncologist.12-5-610

13. Califano R, Tariq N, Compton S, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs. 2015;75(12):1335-1348. doi:10.1007/s40265-015-0434-6

14. Hirsh V, Blais N, Burkes R, Verma S, Croitoru K. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol. 2014;21(6):329-336. doi:10.3747/co.21.2241

15. Riely GJ, Neal JW, Camidge DR, et al. Activity and safety of mobocertinib (TAK-788) in previously treated non–small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial. Cancer Discov. 2021;11(7):1688-1699. doi:10.1158/2159-8290.CD-20-1598

16. Zhou C, Ramalingam SS, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7(12):e214761. doi:10.1001/jamaoncol.2021.4761